Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy Study in NTG, POAG, Glaucoma Suspect, Ocular Hypertension Patients With Diagnosed Prostaglandin Associated Peri-orbitopathy Switching From Preserved Prostaglandin Analogues Monotherapy to Omidenepag Isopropyl

NCT05279716 is registered in ClinicalTrials.gov with Santen Pharmaceutical Asia Pte. Ltd. as lead sponsor.

NCT NCT05279716
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05279716 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy Study in NTG, POAG, Glaucoma Suspect, Ocular Hypertension Patients With Diagnosed Prostaglandin Associated Peri-orbitopathy Switching From Preserved Prostaglandin Analogues Monotherapy to Omidenepag Isopropyl
Lead sponsor
Santen Pharmaceutical Asia Pte. Ltd.
Phase
Phase 4
Overall status
Unknown status
Start date
February 15, 2022
Completion date
November 20, 2023
Enrollment
150 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

glaucoma, suspect, normal tension glaucoma, ocular hypertension, primary open-angle glaucoma